Saturday 17 October 2026
Export DNLI’s income statement to Excel — free account
Denali Therapeutics Inc.
DNLI Healthcare Biotechnology
In the quarter to June 2026, revenue fell 89.7%, EPS grew 5.56%, free cash flow fell 22.9% and total debt fell 1.76%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
17.56
0.78
−4.25%
Follow DNLI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (54.93%) | (49.59%) | (45.69%) | (44.44%) |
+8 more TTM periods Free account |
|
| (44.01%) | (40.04%) | (40.69%) | (39.75%) | ||
ROIC |
(260.54%) | 0.00% | (229.23%) | (409.82%) | |
Return on Tangible Assets |
(71.65%) | (52.68%) | (59.97%) | (58.94%) | |
Average Days of Receivables |
4.79 | — | — | — | |
Free Cash Flow per Share |
(2.34) | (2.25) | (2.44) | (2.38) | |
Free Cash Flow |
(437.46) | (419.23) | (422.10) | (410.85) | |
Capital Expenditures |
(3.42) | (6.89) | (9.50) | (13.07) | |
| Other line items | |||||
Cash ROIC |
(28.20%) | (21.84%) | (22.37%) | (23.08%) | |
Accounts Receivable Turnover |
152.28 | — | — | — | |
Accounts Payable Turnover |
1.13 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
335.71 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
117.69 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
134.02% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
48.41% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
31.80% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.85 | 0.81 | 0.81 | 0.80 | |
Depreciation/Fixed assets |
0.12 | 0.08 | 0.02 | (0.09) | |
Capex/Depreciation |
(0.58) | (1.69) | (10.22) | 2.84 | |
Revenue per Share |
1.60 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.32) | (2.21) | (2.39) | (2.31) | |
Capex per Share |
(0.02) | (0.04) | (0.05) | (0.08) | |
Capex to Sales |
0.01 | 0.00 | 0.00 | 0.00 |
Columns are period end dates